Is the arginine-nitric oxide pathway involved in the pathogenesis of schizophrenia?

Basit Öğe Kaydı
dc.authoridKocyigit, Abdurrahim/0000-0003-2335-412X
dc.authoridYanik, Medaim/0000-0001-5936-0017
dc.authorwosidzoroglu, suleyman s/B-2077-2012
dc.authorwosidZoroglu, Salih/ABD-8029-2020
dc.authorwosidVural, Hüseyin/B-3300-2016
dc.authorwosidKocyigit, Abdurrahim/P-8685-2019
dc.contributor.authorYanik, M
dc.contributor.authorVural, H
dc.contributor.authorKocyigit, A
dc.contributor.authorTutkun, H
dc.contributor.authorZoroglu, SS
dc.contributor.authorHerken, H
dc.contributor.authorSavas, HA
dc.date.accessioned2024-08-04T20:13:13Z
dc.date.available2024-08-04T20:13:13Z
dc.date.issued2003
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThe reciprocal regulation of arginase and nitric oxide synthase (NOS) in L-arginine-metabolizing pathways has been demonstrated. There are various evidences of the role of the nitric oxide (NO) in several neuropsychiatric disorders including schizophrenia. However, there is no study which has investigated the role of arginase as an important part of the arginine regulatory system affecting NOS activity in schizophrenia. This study aims to investigate arginase, manganese (Mn) and total nitrite levels (a metabolite of NO) and their relationship to the arginine-NO pathway in patients with schizophrenia. Arginase activities, Mn and total nitrite levels were measured in plasma from 46 patients with schizophrenia and 32 healthy control subjects. Plasma arginase activities and Mn were found to be significantly lower and total nitrite level higher in patients with schizophrenia compared with controls. Our results suggest that the arginine-NO pathway is involved in the pathogenesis of schizophrenia. Copyright (C) 2003 S. Karger AG, Basel.en_US
dc.identifier.doi10.1159/000070010
dc.identifier.endpage65en_US
dc.identifier.issn0302-282X
dc.identifier.issn1423-0224
dc.identifier.issue2en_US
dc.identifier.pmid12707486en_US
dc.identifier.scopus2-s2.0-0037266247en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage61en_US
dc.identifier.urihttps://doi.org/10.1159/000070010
dc.identifier.urihttps://hdl.handle.net/11616/93480
dc.identifier.volume47en_US
dc.identifier.wosWOS:000182852600002en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofNeuropsychobiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectarginaseen_US
dc.subjectmanganeseen_US
dc.subjectnitric oxideen_US
dc.subjectschizophreniaen_US
dc.titleIs the arginine-nitric oxide pathway involved in the pathogenesis of schizophrenia?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu